This point from Abbott’s CEO was all we were looking to hear : Q2 Conference Call

This point from Abbott’s CEO was all we were looking to hear in  Q2 Conference Call

We are referring to news about Abbott’s acquisition of St Jude Medical and Alere hitting a rough patch.

While the company had shelled out humongous ~31 billion dollars on combined deal, the deal had witnessed a hiccup when FTC asked company for more documents in case of St Jude, and for Alere, it was the subpoena from DOJ that made us feel about the deals falling apart.

In the recent Q2 conference call Miles White, CEO and chairman of Abbott assured that everything in terms of these two deals is on right track, and there is nothing to worry about.

Medtech players are known for their big cash shell out when it comes to acquisitions, Medtronic acquisition of Covidien, BD’s acquisition of Care Fusion and Pfizer acquisition of Hospira, just goes about showing how big of a cheque medtech behemoths sign-off during acquisitions.

But the story does not end there for medtech OEMs, they have to go through numerous regulatory checks & approvals before acquiring companies. Abbott though had signed of a massive ~31 billion dollar cheque for St Jude and Alere, it still had to go through challenging tasks lined next.

Miles White assurance on the deals was all the medtech fraternity was awaiting for. With closure of these deals,medtech consolidates further, which sure will entail more dynamics change for medtech industry.

For more updates follow Medical Device Trends

Advertisements

Medtech M&ATrends Tracker

Medtech M&A Trends Tracker is your one post stop to understand all that is happening in medtech M&A arena. News source: Fierce Biotech,MDDI,Mass Device and others, Profile Source: Social Media Platform

It captures basic company details and other associated data for readers across globe.

Abbott, St. Jude’s $25B tie-up delayed by FTC request

Philips acquires Wellcentive, boosts connected care offerings

What is happening in leadless pacemaker market?

Untitled

Image Courtesy of EBR systems

Should we or should we not remove the cables from our devices? – Is the question that entire medical device OEM family is asking to its R&D team.

Though majority of the players are still seeking answer to this question, pacemaker suppliers are believed to have frozen on their answer. They have picked up the choice of going leadless / wireless. Below are some of the activities that took place around leadless pacemakers in recent past and paint a picture of  where the sector is heading  in terms of innovation.

Approvals, Funding, Clinical Trials, Law-suits, Acquisitions

First leadless pacemaker hit the market in 2011 from CRM device pioneer St Jude Medical. Thanks to its initial investment on Nanostim that gave an opportunity to the company to buy the latter’s assets and gets an easy entry into booming leadless market.

Nanostim choose European market to debut its technology.Though it had an early hiccups, it’s believed to have come on track soon enough, avoiding the industry’s uncalled criticism on innovative solution. Path of leadless pacemaker was then chosen by Medtronic, medtech behemoth known for its product diversity and huge therapeutic focus. Medtronic launched its device: Micra in April 2015.

The only medtech giant who was missing from the party was BSC, which on its recent investor day expressed interest of venturing into market, market which is projected to generate overall sales of USD 700 million by year 2016.

While the leaders of the industry are structuring their growth strategies, start-ups are closing funding rounds. One such company is EBR systems which has been backed by Split Rock Partners and SV Life Sciences. EBR system’s technology platform recently received CE mark, and is different from other leadless pacemaker in terms of area of impulse delivery. While the Medtronic’s and St Jude products provide the impulse to right ventricle, EBS’s WiSE powers left ventricle.

After proving its point  in EU markets, players have commenced their journey into US geography. Both St Jude and Medtronic have kick-started their individual trials for FDA submission, and are likely to share the study results in coming days.

Leadless pacemaker market has been an interesting sub-category to watch, primarily because of issues that it addresses from its counterparts (conventional pacemakers). Casualties from the traditional platform had been the talk of the medtech town, where riata lead failure and Medtronic pacemakers issue have been wakening events for the entire medical device industry. While the former event resulted in St Jude shelling out more than USD 10 million in the form of settlements, latter resulted in increased emphasis on post market surveillance.

Conclusion:

Leadless pacemakers have put a lot of questions to rest, but industry always demands for more. This brings to our final point, on where OEMs should pause & celebrate on their pacemaker developement landmark.

All the current solutions are around single side impulse delivery and what would really change the face of cardiac rhythm management, is a  single pacemaker capable of delivering to both sides of the heart. St Jude Medical, who has made claims of working on similar device type surely seems to have an upper hand in comparison to its counterparts. What would be good to see is, start-ups channelizing their effort to develop similar platform. This would give an opportunity for established players to either  fund the technology or probably acquire it.

Number of Medical Device Approvals in Aug 2015

Numbers can make a difference. Their usage at the right time and right place creates huge impact for an individual, team or an organization. Medical device trends has set its eye on these numbers and longs to capture the same for their viewers, catch is, it is only around medtech industry.

Medtech Product Approvals is regulatory snapshot on device types and companies that have recently gained agencies green flag for product sales across various geographies.

Drop us suggestion, if you wish to add any further elements to the versions and we will try incorporating the same in our monthly issues.

MDT Approval : Downloadable File

MDT Approval

For More Updates

Subscribe to MD Trends

Your Online Trend Tracker

Medical Device Trends Product Approval :Must Check Out Numbers

Medical Device Trends Product Approval snapshot captures all the product approval stats of the month and runs a quick analytical check on major events and products that faced FDA/other regulatory body scrutiny.

To get a continuous snapshot of the monthly dossier subscribe to Medical Device Trends: Your Online Trend Tracker

Also leave us a mail at contactus@medicaldevicetrend.com for continuous access to MDT features.

Attachment to Dashboard:Medical Device Trends Product Approvals

Medical Device Trends Product Approvals

Follow us on Twitter @MDT or LinkedIn Group : Medical Device Trends

Medical Device Trends Special Feature

Medical device trends new add-on, MDT :SF ( Medical device trends : special feature) captures best news feature of the day/week/month for its subscribers.150 words quick summary on news article makes readers aware of top notch med-tech stories that eventually contribute to industry’s trends. Subscribe it to know the most talked medtech news. MDT: SF ( Medical device trends: Special feature) :Special Features MDT

MDT SF

For more updates on medtech, Follow Medical Device Trends Your Online Trend Tracker ( Supporting 50000+ medtech readers around the globe) http://www.medicaldevicetrend.com Subscribe to Medical Device Trends by following the website and leaving a mail at contactus@medicaldevicetrend.com Mail requests will enable MD Trends to send you a daily and monthly notifications on current and future products